Genevoyager (Wuhan) Co. is a biotechnology company specializing in CRO/CDMO services for gene therapy products. Utilizing its proprietary One-Bac 4.0 system, an insect baculovirus platform, the company enhances large-scale production of AAV vectors with improved yield and infectivity. In 2023, Genevoyager inaugurated a 68,000-sq.-ft. cGMP-compliant facility in Wuhan, China, equipped with five viral vector production lines and a fill/finish line, adhering to international regulatory standards. The company offers comprehensive services, including viral vector research and development, preclinical efficacy evaluation, CMC development, quality assurance and control, and GMP production.